Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H9NO6 |
| Molecular Weight | 191.1388 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O
InChI
InChIKey=YWXYYJSYQOXTPL-JGWLITMVSA-N
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5-,6-/m1/s1
| Molecular Formula | C6H9NO6 |
| Molecular Weight | 191.1388 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2895614 |
0.75 mM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Rhabdomyolysis in a patient receiving ranolazine and simvastatin. | 2010-11-01 |
|
| Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. | 2010-10 |
|
| Differences between nitrates: role of isosorbide 2-mononitrate. | 2010-07 |
|
| Angiographic documentation of coronary artery spasm induced by anesthesia. | 2010-06 |
|
| Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. | 2010-04 |
|
| Management of a case of endobronchial blood clot in the post operative period. | 2009-04 |
|
| Death following bilateral complete Achilles tendon rupture in a patient on fluoroquinolone therapy: a case report. | 2009-01-06 |
|
| Effect of large volume injection of hydrophobic solvents on the retention of less hydrophobic pharmaceutical solutes in RP-LC. | 2008-09 |
|
| Chronic nitrate therapy in patients with angina with comorbidity. | 2006-06-15 |
|
| Comparison of isosorbide mononitrate (Mono Mack) and misoprostol (Cytotec) for cervical ripening in the first trimester missed abortion. | 2005-12 |
|
| "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. | 2002-12 |
|
| Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. | 2002-09 |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002-07 |
|
| [Treatment of esophageal varices]. | 2001-03-12 |
Sample Use Guides
Isosorbide 5-mononitrate (IS-5-MN) and isosorbide 2-mononitrate (IS-2-MN) kinetics were studied in two groups of young healthy subjects after intravenous injection of 5 mg of both and after oral doses of 20 mg of IS-2-MN and 10, 15, and 20 mg of IS-5-MN.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6498631
2-isosorbide mononitrate (2-ISMN) is able to relax phenylephrine-contracted rabbit aortic rings (ED50, 1.8 uM)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:48:15 GMT 2025
by
admin
on
Mon Mar 31 21:48:15 GMT 2025
|
| Record UNII |
21BMF8FI0K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB35553
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
100000128484
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
1353113
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
16106-20-0
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
62989
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
240-271-4
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
21BMF8FI0K
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY | |||
|
DTXSID40873331
Created by
admin on Mon Mar 31 21:48:15 GMT 2025 , Edited by admin on Mon Mar 31 21:48:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
MINOR
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|